Cytoplasmic, but not nuclear, p16 expression may signal poor prognosis in high-grade astrocytomas
Cytoplasmic, but not nuclear, p16 expression may signal poor prognosis in high-grade astrocytomas
复制标题
DOI：
10.1007/s11060-005-9037-5
复制
发表时间：
2006-05-01
影响因子：
3.9
通讯作者：
Kurisu, Kaoru
中科院分区：
文献类型：
--
作者：
Arifin, Muhamad Thohar;Hama, Seiji;Kurisu, Kaoru
背景资料：为探讨高级别星形细胞瘤中p16蛋白胞浆定位对预后的影响，采用免疫组化方法检测20例间变性星形细胞瘤和42例胶质母细胞瘤中p16蛋白的表达，并分析其胞浆和胞核表达与预后的关系。p16胞浆表达与预后不良有关。另一方面，没有相关性，观察p16核表达和患者survival.Conclusion：p16的胞浆免疫反应性似乎是一个不利的预后指标在高级别星形细胞瘤患者。p16蛋白表达定位是判断预后的重要依据.
Background: The negative consequences of the cytoplasmic localization of p16 in patients with high-grade astrocytomas, on their prognosis, was investigated.Methods: p16 Expression was examined in 20 anaplastic astrocytoma and 42 glioblastoma patients by immunohistochemical analysis, and the relationship between both cytoplasmic and nuclear p 16 expression and prognosis analyzed.Results: The cytoplasmic expression of p16 statistically correlated with poor prognosis. On the other hand, no correlation was observed between p16 nuclear expression and patient survival.Conclusion: The cytoplasmic immunoreactivity of p 16 appears to be an unfavorable prognostic indicator in high-grade astrocytoma patients. The localization of p 16 expression should be determined when evaluating the prognosis of these patients.